Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist

por Fox, Edward J., Buckle, Guy J., Singer, Barry, Singh, Vibhuti, Boster, Aaron
Publicado 2019

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate

por Nicholas, Jacqueline Ann, Boster, Aaron Lee, Imitola, Jaime, O’Connell, Colleen, Racke, Michael Karl
Publicado 2014

Iron Is a Sensitive Biomarker for Inflammation in Multiple Sclerosis Lesions

por Mehta, Veela, Pei, Wei, Yang, Grant, Li, Suyang, Swamy, Eashwar, Boster, Aaron, Schmalbrock, Petra, Pitt, David
Publicado 2013

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database

por Boster, Aaron, Nicholas, Jacqueline, Wu, Ning, Yeh, Wei-Shi, Fay, Monica, Edwards, Michael, Huang, Ming-Yi, Lee, Andrew
Publicado 2017

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data

por Nicholas, Jacqueline, Boster, Aaron, Wu, Ning, Yeh, Wei-Shi, Fay, Monica, Kendter, Jon, Huang, Ming-Yi, Lee, Andrew
Publicado 2017

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

por Olsson, Tomas, Boster, Aaron, Fernández, Óscar, Freedman, Mark S, Pozzilli, Carlo, Bach, Doris, Berkani, Ouali, Mueller, Markus S, Sidorenko, Tatiana, Radue, Ernst-Wilhelm, Melanson, Maria
Publicado 2014

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

por Horáková, Dana, Boster, Aaron, Bertolotto, Antonio, Freedman, Mark S, Firmino*, Isabel, Cavalier, Steven J, Jacobs*, Alan K, Thangavelu*, Karthinathan, Daizadeh, Nadia, Poole*, Elizabeth M, Baker, Darren P, Margolin*, David H, Ziemssen, Tjalf
Publicado 2020

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

por Van Wijmeersch, Bart, Singer, Barry A, Boster, Aaron, Broadley, Simon, Fernández, Óscar, Freedman, Mark S, Izquierdo, Guillermo, Lycke, Jan, Pozzilli, Carlo, Sharrack, Basil, Steingo, Brian, Wiendl, Heinz, Wray, Sibyl, Ziemssen, Tjalf, Chung, Luke, Margolin, David H, Thangavelu, Karthinathan, Vermersch, Patrick
Publicado 2019

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

por Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Publicado 2021

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

por Coles, Alasdair J, Jones, Joanne L, Vermersch, Patrick, Traboulsee, Anthony, Bass, Ann D, Boster, Aaron, Chan, Andrew, Comi, Giancarlo, Fernández, Óscar, Giovannoni, Gavin, Kubala Havrdova, Eva, LaGanke, Christopher, Montalban, Xavier, Oreja-Guevara, Celia, Piehl, Fredrik, Wiendl, Heinz, Ziemssen, Tjalf
Publicado 2021

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studi...

por Comi, Giancarlo, Alroughani, Raed, Boster, Aaron L, Bass, Ann D, Berkovich, Regina, Fernández, Óscar, Kim, Ho Jin, Limmroth, Volker, Lycke, Jan, Macdonell, Richard AL, Sharrack, Basil, Singer, Barry A, Vermersch, Patrick, Wiendl, Heinz, Ziemssen, Tjalf, Jacobs, Alan, Daizadeh, Nadia, Rodriguez, Claudio E, Traboulsee, Anthony
Publicado 2019

Toward Precision Phenotyping of Multiple Sclerosis

por Pitt, David, Lo, Chih Hung, Gauthier, Susan A., Hickman, Richard A., Longbrake, Erin, Airas, Laura M., Mao-Draayer, Yang, Riley, Claire, De Jager, Philip Lawrence, Wesley, Sarah, Boster, Aaron, Topalli, Ilir, Bagnato, Francesca, Mansoor, Mohammad, Stuve, Olaf, Kister, Ilya, Pelletier, Daniel, Stathopoulos, Panos, Dutta, Ranjan, Lincoln, Matthew R.
Publicado 2022

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

por Barclay, Krista, Carruthers, Robert, Traboulsee, Anthony, Bass, Ann D., LaGanke, Christopher, Bertolotto, Antonio, Boster, Aaron, Celius, Elisabeth G., de Seze, Jérôme, Cruz, Dionisio Dela, Habek, Mario, Lee, Jong-Mi, Limmroth, Volker, Meuth, Sven G., Oreja-Guevara, Celia, Pagnotta, Patricia, Vos, Cindy, Ziemssen, Tjalf, Baker, Darren P., Wijmeersch, Bart Van
Publicado 2019